Beyond GLP-1: GIP and Glucagon Dual-Pathway Medications Emerge

STAT reported emergence of a new drug class targeting GIP and glucagon receptors, rather than GLP-1 itself, to reduce nausea side effects. Expansion across multiple disease indications is key.